Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyramza and irinotecan in advanced gastric or GEJ adenocarcinoma
NCT03141034Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2017
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Washington University School of Medicine. Started Nov 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03141034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141034.